Mindwalk identified TDP-43 antibodies that selectively target abnormal protein clumps linked to ALS and other diseases.
Aperture Therapeutics is advancing APRTX-003, an RNA-based antisense therapy targeting MMP9, as a potential ALS treatment.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback